Dual-faced guardians: SGLT2 inhibitors’ kidney protection and health challenges: a position statement by Kasralainy nephrology group (KANG)
Abstract Background SGLT2 inhibitors represent a revolutionary drug class that delivers benefits exceeding those of diabetes management alone. Initially approved for type 2 diabetes management, research continually demonstrates their protective effects on kidney function across several nephrological...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-06-01
|
| Series: | Diabetology & Metabolic Syndrome |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s13098-025-01790-w |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850221802323705856 |
|---|---|
| author | Amin Roshdy Soliman Mohamed Elkhatib Sahier El-Khashab Rasha Ahmed Darwish Ahmed Fayed Tarek S. Abdelaziz Hany Hammad Rabab Mahmoud Ahmed Hoda Abdelhamid Maamoun |
| author_facet | Amin Roshdy Soliman Mohamed Elkhatib Sahier El-Khashab Rasha Ahmed Darwish Ahmed Fayed Tarek S. Abdelaziz Hany Hammad Rabab Mahmoud Ahmed Hoda Abdelhamid Maamoun |
| author_sort | Amin Roshdy Soliman |
| collection | DOAJ |
| description | Abstract Background SGLT2 inhibitors represent a revolutionary drug class that delivers benefits exceeding those of diabetes management alone. Initially approved for type 2 diabetes management, research continually demonstrates their protective effects on kidney function across several nephrological conditions, including acute kidney injury (AKI), chronic kidney disease (CKD), dialysis-dependent kidney failure, anemia, metabolic bone disease, polycystic kidney disease (PKD), glomerulonephritis, and kidney transplantation. Purpose This study aims to identify how SGLT2 inhibitors modify nephrological care by investigating their mechanisms of action, therapeutic outcomes, and potential applications in multiple kidney diseases. It summarizes clinical trial data alongside mechanistic insights to provide a comprehensive assessment of therapeutic outcomes beyond diabetes mellitus. Findings Numerous clinical studies have demonstrated that SGLT2 inhibitors reduce kidney disease progression in patients with or without diabetes. These findings indicate that SGLT2 inhibitors provide kidney protection by enhancing tubuloglomerular feedback, improving renal blood flow, and reducing inflammation and ischemic tissue damage. They also provide cardiovascular benefits to dialysis patients while maintaining effective blood flow during dialysis. SGLT2 inhibitors should not be used in autosomal dominant polycystic kidney disease (ADPKD) outside clinical trials. The potential impact of SGLT2 inhibitors on bone mineral health, particularly regarding bone mineral density (BMD) reduction and fracture risk, requires careful consideration, especially in patients with pre-existing bone health concerns. Kidney transplant recipients benefit from SGLT2 inhibitors’ protective effects on kidney health and assistance with diabetes management; however, further research is needed on drug compatibility with immunosuppressants and infection prevention. |
| format | Article |
| id | doaj-art-991456bdccca453a9d23d0ddbd0d0992 |
| institution | OA Journals |
| issn | 1758-5996 |
| language | English |
| publishDate | 2025-06-01 |
| publisher | BMC |
| record_format | Article |
| series | Diabetology & Metabolic Syndrome |
| spelling | doaj-art-991456bdccca453a9d23d0ddbd0d09922025-08-20T02:06:35ZengBMCDiabetology & Metabolic Syndrome1758-59962025-06-0117111610.1186/s13098-025-01790-wDual-faced guardians: SGLT2 inhibitors’ kidney protection and health challenges: a position statement by Kasralainy nephrology group (KANG)Amin Roshdy Soliman0Mohamed Elkhatib1Sahier El-Khashab2Rasha Ahmed Darwish3Ahmed Fayed4Tarek S. Abdelaziz5Hany Hammad6Rabab Mahmoud Ahmed7Hoda Abdelhamid Maamoun8Internal Medicine and Nephrology Department, Faculty of Medicine, Cairo UniversityInternal Medicine and Nephrology Department, Faculty of Medicine, Cairo UniversityInternal Medicine and Nephrology Department, Faculty of Medicine, Cairo UniversityInternal Medicine and Nephrology Department, Faculty of Medicine, Cairo UniversityInternal Medicine and Nephrology Department, Faculty of Medicine, Cairo UniversityInternal Medicine and Nephrology Department, Faculty of Medicine, Cairo UniversityInternal Medicine and Nephrology Department, Faculty of Medicine, Cairo UniversityInternal Medicine and Nephrology Department, Faculty of Medicine, Cairo UniversityInternal Medicine and Nephrology Department, Faculty of Medicine, Cairo UniversityAbstract Background SGLT2 inhibitors represent a revolutionary drug class that delivers benefits exceeding those of diabetes management alone. Initially approved for type 2 diabetes management, research continually demonstrates their protective effects on kidney function across several nephrological conditions, including acute kidney injury (AKI), chronic kidney disease (CKD), dialysis-dependent kidney failure, anemia, metabolic bone disease, polycystic kidney disease (PKD), glomerulonephritis, and kidney transplantation. Purpose This study aims to identify how SGLT2 inhibitors modify nephrological care by investigating their mechanisms of action, therapeutic outcomes, and potential applications in multiple kidney diseases. It summarizes clinical trial data alongside mechanistic insights to provide a comprehensive assessment of therapeutic outcomes beyond diabetes mellitus. Findings Numerous clinical studies have demonstrated that SGLT2 inhibitors reduce kidney disease progression in patients with or without diabetes. These findings indicate that SGLT2 inhibitors provide kidney protection by enhancing tubuloglomerular feedback, improving renal blood flow, and reducing inflammation and ischemic tissue damage. They also provide cardiovascular benefits to dialysis patients while maintaining effective blood flow during dialysis. SGLT2 inhibitors should not be used in autosomal dominant polycystic kidney disease (ADPKD) outside clinical trials. The potential impact of SGLT2 inhibitors on bone mineral health, particularly regarding bone mineral density (BMD) reduction and fracture risk, requires careful consideration, especially in patients with pre-existing bone health concerns. Kidney transplant recipients benefit from SGLT2 inhibitors’ protective effects on kidney health and assistance with diabetes management; however, further research is needed on drug compatibility with immunosuppressants and infection prevention.https://doi.org/10.1186/s13098-025-01790-wSGLT2 inhibitorsKidney disease managementRenoprotection |
| spellingShingle | Amin Roshdy Soliman Mohamed Elkhatib Sahier El-Khashab Rasha Ahmed Darwish Ahmed Fayed Tarek S. Abdelaziz Hany Hammad Rabab Mahmoud Ahmed Hoda Abdelhamid Maamoun Dual-faced guardians: SGLT2 inhibitors’ kidney protection and health challenges: a position statement by Kasralainy nephrology group (KANG) Diabetology & Metabolic Syndrome SGLT2 inhibitors Kidney disease management Renoprotection |
| title | Dual-faced guardians: SGLT2 inhibitors’ kidney protection and health challenges: a position statement by Kasralainy nephrology group (KANG) |
| title_full | Dual-faced guardians: SGLT2 inhibitors’ kidney protection and health challenges: a position statement by Kasralainy nephrology group (KANG) |
| title_fullStr | Dual-faced guardians: SGLT2 inhibitors’ kidney protection and health challenges: a position statement by Kasralainy nephrology group (KANG) |
| title_full_unstemmed | Dual-faced guardians: SGLT2 inhibitors’ kidney protection and health challenges: a position statement by Kasralainy nephrology group (KANG) |
| title_short | Dual-faced guardians: SGLT2 inhibitors’ kidney protection and health challenges: a position statement by Kasralainy nephrology group (KANG) |
| title_sort | dual faced guardians sglt2 inhibitors kidney protection and health challenges a position statement by kasralainy nephrology group kang |
| topic | SGLT2 inhibitors Kidney disease management Renoprotection |
| url | https://doi.org/10.1186/s13098-025-01790-w |
| work_keys_str_mv | AT aminroshdysoliman dualfacedguardianssglt2inhibitorskidneyprotectionandhealthchallengesapositionstatementbykasralainynephrologygroupkang AT mohamedelkhatib dualfacedguardianssglt2inhibitorskidneyprotectionandhealthchallengesapositionstatementbykasralainynephrologygroupkang AT sahierelkhashab dualfacedguardianssglt2inhibitorskidneyprotectionandhealthchallengesapositionstatementbykasralainynephrologygroupkang AT rashaahmeddarwish dualfacedguardianssglt2inhibitorskidneyprotectionandhealthchallengesapositionstatementbykasralainynephrologygroupkang AT ahmedfayed dualfacedguardianssglt2inhibitorskidneyprotectionandhealthchallengesapositionstatementbykasralainynephrologygroupkang AT tareksabdelaziz dualfacedguardianssglt2inhibitorskidneyprotectionandhealthchallengesapositionstatementbykasralainynephrologygroupkang AT hanyhammad dualfacedguardianssglt2inhibitorskidneyprotectionandhealthchallengesapositionstatementbykasralainynephrologygroupkang AT rababmahmoudahmed dualfacedguardianssglt2inhibitorskidneyprotectionandhealthchallengesapositionstatementbykasralainynephrologygroupkang AT hodaabdelhamidmaamoun dualfacedguardianssglt2inhibitorskidneyprotectionandhealthchallengesapositionstatementbykasralainynephrologygroupkang |